Joachim Kreuzburg - Sartorius Stedim Chairman of The Board and CEO

SDMHF Stock  USD 229.31  9.31  4.23%   

Chairman

Dr. Joachim Kreuzburg has served as Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee of Sartorius Stedim Biotech SA since June 29, 2007. He is also Member of the Company Remuneration Committee. In addition to his duties at the Company, Dr. Kreuzburg held several other mandates, including Vice Chairman of the Supervisory Board of Sartorius Stedim Biotech GmbH and Member of the Board of Directors of Sartorius Mechatronics Japan K.K., among others. He started his career working as a Scientific Assistant at the Research Institute on Solar Energy of Lower Saxony from 1992 to 1995. Subsequently, he was Scientific Assistant at the department of Economics of Hannover University until 1999. He then joined Sartorius AG as Director of Finance and Investors Relations on May 1, 1999. In November 2002, he was appointed Member of the Management Board of Sartorius AG and Director of Finance, Administration and Investors Relations. Between May 2003 and November 2005, Dr. Kreuzburg served as Spokesperson of the Management Board of Sartorius AG. Since November 11, 2005, he was Chairman of the Management Board of Sartorius AG since 2007.
Age 58
Tenure 17 years
Professional MarksPh.D
Phone33 4 42 84 56 00
Webhttps://www.sartorius.com
Kreuzburg holds a degree in Mechanical Engineering from Gottfried Wilhelm Leibniz Universitaet Hannover, a Doctorate degree in Political Science and a Doctorate degree in Economics.

Sartorius Stedim Management Efficiency

The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3306 %, meaning that it generated $0.3306 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 521.07 M in total debt with debt to equity ratio (D/E) of 0.5, which is about average as compared to similar companies. Sartorius Stedim Biotech has a current ratio of 1.46, which is within standard range for the sector. Debt can assist Sartorius Stedim until it has trouble settling it off, either with new capital or with free cash flow. So, Sartorius Stedim's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sartorius Stedim Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sartorius to invest in growth at high rates of return. When we think about Sartorius Stedim's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CHAIRMAN Age

Kevin CornwellUtah Medical Products
77
Harel GadotMicrobot Medical
51
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 10409 people. Sartorius Stedim Biotech [SDMHF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Sartorius Stedim Biotech Leadership Team

Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations
Heiko Imhl, VP Relations
Olivier Guitard, Head BPS
Joachim Kreuzburg, Chairman of The Board and CEO
Benedikt Orzelek, Investor Relations Contact
John Mackay, Sales Marketing

Sartorius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sartorius Stedim Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the Sartorius Stedim Biotech information on this page should be used as a complementary analysis to other Sartorius Stedim's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Sartorius Pink Sheet analysis

When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Please note, there is a significant difference between Sartorius Stedim's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sartorius Stedim is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sartorius Stedim's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.